EMA Authorised: Xiliarx (vildagliptin) — Novartis Europharm Limited

View source ↗

Summary

The EMA authorised Xiliarx, a vildagliptin-containing medicine, for Type 2 diabetes mellitus, with Novartis Europharm Limited as the marketing authorization hol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Xiliarx (vildagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Novartis Europharm Limited. Decision date: 05/12/2025